antitumor

NKTR-105 Demonstrates Superior Antitumor Activity and Improved Pharmacokinetics Over Docetaxel in Preclinical Studies Presented at AACR

DENVER and SAN CARLOS, Calif., April 22 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR ) presented data today at the American Association for Cancer Research (AACR) 100th Annual Meeting demonstrating that NKTR-105, a novel PEGylated form of docetaxel, has superior antitumor activity...

Benzotiophene derivatives exhibit antitumor activity

Raquel Villar Becares, Ph.D, student at Public University of Navarre has reported in her thesis that benzo[b]tiophene 1,1 dioxide is found to have anti-cancer effects//. She tested 24 compounds isolated from the derivatives and found 23 compounds from it had antitumor activity when tested in invitr...

EntreMed Reports Second Quarter 2009 Financial Results

...nase inhibitor with a unique kinase selectivity profile and multiple mechanisms of action. Preclinical studies with ENMD-2076 demonstrated significant antitumor activity, including tumor regression, in multiple solid and hematological malignancies. ENMD-2076 has been shown to inhibit a distinct profile of angi...

JNCI news brief: Antibody linked to chemotherapy drug inhibits ovarian cancer in lab

... linked to a chemotherapy drug, showed substantial antitumor activity in ovarian cancer cell lines and in mice,...tically significant difference. In cell lines, its antitumor effects were also statistically significantly rela...a novel EphA2-targeted immunoconjugate with potent antitumor activity in ovarian carcinoma. Further preclinical...

Centocor Ortho Biotech Statement on the FDA ODAC Opinion Regarding Trabectedin for Relapsed Ovarian Cancer

...n. The final decision regarding approval of the drug will be made by the FDA. About Trabectedin Trabectedin is a novel cytotoxic antitumor agent that was originally derived from the marine tunicate, Ecteinascidia turbinata. The compound is now produced synthetically. Trabectedin binds t...

Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1/2 Study of MM-111, a Bispecific Antibody to ErbB2/3

...t. Preclinical studies have demonstrated that the bispecific approach shows antitumor activity in a wide range of tumor types. The current Phase 1/2 study will e...ical studies of MM-111 have demonstrated that the bispecific approach shows antitumor activity in a wide range of tumor types and we are hopeful this will transl...

Novel light-sensitive compounds show promise for cancer therapy

...ism for how the enzyme nitrile hydratase is photoregulated by nitric oxide. This process gave us the idea of making light-sensitive metal nitrosyls as antitumor drugs," Mascharak said. ...

Nicotine Receptors Could Be Lung Cancer Treatment Target

...mice and 2.1-fold over untreated mice. "The results of this study show that α-CbT, a powerful, high-affinity α-7-nAChR inhibitor, induces antitumor activity against NSCLC by triggering apoptosis," wrote Patrizia Russo of the Lung Cancer Unit of the National Cancer Research Institute in Genoa, Ital...

Defeating nicotine's double role in lung cancer

...the no-treatment controls (p=0.0005). "The results of this study show that α-CbT, a powerful, high-affinity α-7-nAChR inhibitor, induces antitumor activity against NSCLC by triggering apoptosis," wrote Dr. Russo. "The prolonged survival of α-CbT-treated animals in our mouse model of NSCLC is...

Cylene to Announce New Data on Its First-in-Class Oral CK2 Inhibitor Against Cancer at BIO Conference

...e 2009 BIO International Convention on Wednesday, May 20th at 4:40 pm. William G. Rice, Ph.D., Cylene's president and CEO, will discuss the mechanism, antitumor properties and tumor selectivity of CX-4945, the Company's oral protein kinase inhibitor currently in Phase I clinical trials. This proprietary compo...

antitumor in Medical Technology

Semafore's SF1126 Exhibits Antitumor and Antiangiogenic Activity

INDIANAPOLIS, Jan. 9 /PRNewswire/ -- Semafore Pharmaceuticals Inc. today announced that a paper published in Cancer Research (2008; Vol. 68, Issue 1: 206-215) reports that SF1126, the company's lead product candidate, exhibits antitumor and antiangiogenic activity. The paper, entitled "A Vas...

Kosan Presents Phase 1 Data Showing Antitumor Activity and Safety Profile of Epothilone KOS-1584 at AACR/NCI/EORTC Meeting

HAYWARD, Calif., Oct. 23 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated (Nasdaq: KOSN ) presented updated data today from a Phase 1 clinical trial showing that KOS-1584/R1645, an epothilone under co-development with Roche, demonstrated antitumor activity and tolerability in patients...

Studies Show Mild Hyperthermia Enhances Antitumor Effects of Alfacell's Onconase

BLOOMFIELD, N.J., March 22, 2007 /PRNewswire-FirstCall/ -- Alfacell Corporation today reported that in vitro studies show mild hyperthermia enhances the therapeutic effects of ONCONASE (ranpirnase), the company's lead investigational drug candidate. In a paper entitled, "Mild hyperthermia predis...

Kosan Presents Preclinical Antitumor and Safety Data On Next-Generation Epothilone KOS-1803 at AACR

HAYWARD, Calif., April 16, 2007 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated today presented preclinical data on KOS-1803, a next-generation epothilone, showing a high level of antitumor activity and a favorable pharmacokinetic and safety profile in a broad range of in vitro tests and ...

EntreMed Presents Multi-Mechanism Antitumor Data for ENMD-1420 in Preclinical Models

Tumor Inhibition Demonstrated in Lung and Colorectal Cancers ROCKVILLE, Md., April 16, 2007 /PRNewswire-FirstCall/ -- EntreMed, Inc. , a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, announced the presentation of results for it...

Abraxis BioScience Presents Results from Pre-Clinical Study That Demonstrates nab-Rapamycin's Robust Antitumor Properties and Ability to Target Intracellular Sites Such as the mTOR Pathway

LOS ANGELES--(BUSINESS WIRE)--Apr 19, 2007 - Abraxis BioScience, Inc. (NASDAQ:ABBI), an integrated, global biopharmaceutical company, presented first-time data from a pre-clinical study evaluating the toxicity and antitumor effect of nab-rapamycin (ABI-009), an albumin-bound mTOR kinase inhibitor, ...

Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO

HAYWARD, Calif., June 04, 2007 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated presented preliminary data from a Phase 2 monotherapy trial showing that tanespimycin demonstrated antitumor activity and tolerability in patients with metastatic melanoma, including one patient with a BRAF mut...

Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing Promising Antitumor Activity in Multiple Myeloma at ASCO

Tanespimycin TIME Registration Program to Begin Third Quarter 2007 HAYWARD, Calif., June 04, 2007 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated presented data from a dose-escalating Phase 1b clinical trial of its lead Hsp90 inhibitor, tanespimycin (KOS-953) in combination with bortezomi...

Kosan Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Epothilone KOS-1584 at ASCO

HAYWARD, Calif., June 04, 2007 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated presented data from a Phase 1 clinical trial showing that KOS-1584/R1645, an epothilone under co-development with Roche, demonstrated promising antitumor activity and tolerability in patients with solid tumors....

Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO

Clinical Benefit Shown in 35% of HER2-Positive Metastatic Breast Cancer Patients HAYWARD, Calif., June 04, 2007 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated presented data from a Phase 1 clinical trial showing that alvespimycin, its second-generation Hsp90 inhibitor, demonstrated promi...

More>>

antitumor in Biological News

Progress toward an antitumor vaccine

How can we induce the body to use its own weapon, the immune system, to battle cancer" In principle, by the same means used against infectious diseases: immunization. The production of a selective vaccine is not a trivial task, however. A team led by Horst Kunst at the University of Mainz has now ...

A longer lasting tumor blocker

... On the heels of dismaying reports that a promising antitumor drug could, in theory, shorten patients' long-term survival, comes a promising study by a Japanese team of researchers that suggests a potentially bet...

Regulation of cell proliferation by the OGF-OGFr axis is dependent on nuclear localization signals

...f the Opioid Growth Factor (OGF, [Met5]-enkephalin), a clinically important antitumor agent, is dependent on nucleocytoplasmic translocation and reliant on the i...t the Opioid Growth Factor (OGF, [Met5]-enkephalin), a clinically important antitumor agent, is dependent on shuttling of the peptide and the OGF receptor from t...

JCI online early table of contents: Jan. 19, 2009

... prostate cancer. Further in vitro analysis revealed that the antibody worked by inducing cancer cells to die and that it synergistically enhanced the antitumor effects of two chemotherapeutic drugs. The researchers therefore suggest that using antibodies that target Pim-1 might of benefit to individuals with ...

13 UCR faculty members recognized by American Association for the Advancement of Science

...nd natural products chemistry of marine invertebrates and bacteria from deep-sea sediments, particularly for the discovery and characterization of new antitumor compounds including salinosporamide A." Stephan von Molnar 65 Ph.D., now at Florida State University: "For seminal research on magnetic polarons, t...

Wistar scientists find key to keeping killer T cells in prime shape for fighting infection, cancer

...t suggests it may be possible to not only dramatically enhance antiviral or antitumor T cell responses, but also to fine tune which response you want to enhance ... role in chronic viral infection. LAG-3, for example, is associated with an antitumor response. These observations may explain why PD-1 blockade did not complete...

Researchers find cancer-inhibiting compound under the sea

... Luesch said that within the next few months he plans to study whether largazole reduces or prevents tumor growth in mice. Luesch has several other antitumor natural products from Atlantic and Pacific cyanobacteria in the pipeline. "We have only scratched the surface of the chemical diversity in the ocea...

Imiquimod, an immune response modifier, is dependent on the OGF-OGFr signaling pathway

...icine, Hershey, Pennsylvania have discovered that the efficacy of imiquimod, a clinically important immune response modifier with potent antiviral and antitumor activity, is dependent on the Opioid Growth Factor (OGF)-OGF receptor (OGFr) axis for its action. This discovery, reported in the August 08 issue of ...

TG2 identified as potential therapeutic target in chemo-resistant ovarian cancer

...opment, while increasing apoptosis," said Sood. Mouse model studies of chemotherapy-sensitive and chemotherapy-resistant models showed considerable antitumor activity both with TG2 siRNA alone and in combination with docetaxel chemotherapy. The combination therapy of TG2 siRNA with docetaxel reduced tumor w...

American Chemical Society's Weekly PressPac -- April 23, 2008

... of cardiotoxicity and minimize the risks of cardiac events in patients, the article notes. MTS ARTICLE #1 FOR IMMEDIATE RELEASE Cardiotoxicity of antitumor Drugs DOWNLOAD FULL TEXT ARTICLE http://dx.doi.org/10.1021/tx800002r CONTACT: Giorgio Minotti, M.D. University Campus Bio-Medico of Rome R...

antitumor in Biological Technology

ANX-514 Reduces Hypersensitivity Reactions Without Impacting Pharmacokinetics or Antitumor Activity in Preclinical Tests

ADVENTRX Presents Results at 2007 AACR-NCI-EORTC International Conference SAN DIEGO, Oct. 25 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (Amex: ANX ), a biopharmaceutical research and development company focused on commercializing proprietary product candidates for the treatment o...

Celator(R) Pharmaceuticals Presents Data on the Activity of CPX-351 Against Leukemia at the European Hematology Association Congress

...data on the pharmacokinetics and pharmacology of CPX-351 from a Phase I study of patients with relapsed or refractory acute leukemias.(1) Evidence of antitumor effect, details of which were presented at the American Society of Hematology (ASH) meeting in late 2008, included complete remissions (CRs) in 1 of 3...

Ascenta Therapeutics Announces Presentation of Promising Results From Clinical Trials of AT-101 in Prostate, Brain, and Lung Cancers at 2009 ASCO Annual Meeting

...l response rates we are seeing in this trial demonstrate strong evidence of antitumor activity in patients with metastatic CRPC," said Gary R. MacVicar, MD, Nort... Reports from two studies in lung cancer also showed promising signals of antitumor effect. The first presentation described results from a randomized, double...

Centocor Ortho Biotech Data to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting

...ng the Boxed WARNINGS, and for the Medication Guide and Patient Instructions for Use. About Trabectedin Trabectedin is a novel cytotoxic antitumor agent that was originally derived from the Caribbean tunicate, Ecteinascidia turbinate ("sea squirt"). The compound is now produced synthetically. ...

Micromet to Present New Clinical Data on Blinatumomab at EHA and on Adecatumumab at ASCO

...ion on June 5, 2009, 5:45 PM. Blinatumomab abstracts can be accessed at http://www.ehaweb.org . (3) Sebastian et al. (2009). Safety and antitumor activity of 3-weekly anti-EpCAM antibody adecatumumab (MT201) in combination with docetaxel for patients with metastatic breast cancer: Results of a m...

EntreMed ENMD-2076 Phase 1 Data to Be Presented at ASCO Annual Meeting

... ENMD-2076 to further define the objectives of safety, pharmacokinetics and antitumor activity. We believe the current clinical program allows us to quickly add...nisms of action. Preclinical studies with ENMD-2076 demonstrate significant antitumor activity, including tumor regression, in multiple solid and hematological m...

Telik Reports Preclinical Results at AACR Annual Meeting

...r cell lines. The resulting apoptosis or senescence of these cells may depend on their p53 status. In vivo, TLK58747 demonstrated significant antitumor activity both orally and parenterally against a wide variety of human tumor types, including breast, pancreatic, prostate, and colorectal carcinomas, ...

Ascenta Therapeutics Announces Results of Preclinical Evaluation of AT-406 in Multiple Cancer Models

... activation of caspase-8 and the death-receptor complex. AT-406 is in late-stage preclinical development and has demonstrated strong single-agent antitumor activity in multiple xenograft models of human cancer, including breast cancer, pancreatic cancer, prostate cancer, and lung cancer. AT-406 has also ...

AEterna Zentaris Presents Two Posters on its PI3K Inhibitor Compound, AEZS-126, at AACR Annual Meeting

...126, a new orally bioavailable PI3K inhibitor with antitumor effects", I. Seipelt, S. Baasner, M. Gerlach, M. T...vo pharmacokinetic experiments and mouse xenograft antitumor studies. Results AEZS-126 was identified...vo pharmacokinetic experiments and mouse xenograft antitumor studies, the oral bioavailability in mice was dete...

Keryx Biopharmaceuticals Presents Encouraging Preclinical Data at Annual Meeting of the American Association of Cancer Research

...targeting of cancer stem cells through inhibition of this signaling pathway represents a rational therapeutic strategy. Abstract 4576: Potent antitumor effects of nab-rapamycin (ABI-009) in combination with kinase inhibitors Erlotinib and Perifosine Author(s): Neil Desai, Osmond D'Cruz, Vuong Tri...

antitumor in Biological Products

Human Topoisomerase I Wild Type from Calbiochem

Description:...regulatory pathways during cell growth and development. Since Topo I can cause large amounts of single-strand DNA breaks it is an important target for antitumor agents. One unit= 1 ng protein. Specific activity: 1 unit/ng protein. 0.1-1 unit (ng) is sufficient for relaxing 0.5 µg of pBR322 supercoiled...
Company:Calbiochem

antitumor in Biological Dictionary

Effector cell

...days after effector cell therapy, elevated levels of activated endogenous ... Both Tc1 and Tc2 effector cell subpopulations induced endogenous antitumor ... The search textbox has an autosuggest feature. ... effector cell . A cell that performs a specific function in response to a stimulus; usu...